SG11201808717QA - Phosphaplatin liquid formulations - Google Patents
Phosphaplatin liquid formulationsInfo
- Publication number
- SG11201808717QA SG11201808717QA SG11201808717QA SG11201808717QA SG11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- phosphaplatin
- liquid formulations
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319047P | 2016-04-06 | 2016-04-06 | |
| PCT/US2017/026139 WO2017176880A1 (en) | 2016-04-06 | 2017-04-05 | Phosphaplatin liquid formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808717QA true SG11201808717QA (en) | 2018-11-29 |
Family
ID=60000715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808717QA SG11201808717QA (en) | 2016-04-06 | 2017-04-05 | Phosphaplatin liquid formulations |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11154529B2 (zh) |
| EP (1) | EP3439650A4 (zh) |
| JP (2) | JP2019510831A (zh) |
| KR (1) | KR102419247B1 (zh) |
| CN (1) | CN109310663B (zh) |
| AU (1) | AU2017246883B2 (zh) |
| BR (1) | BR112018070603A2 (zh) |
| CA (1) | CA3020166A1 (zh) |
| CL (1) | CL2018002848A1 (zh) |
| CO (1) | CO2018011420A2 (zh) |
| EA (1) | EA039525B1 (zh) |
| IL (1) | IL262066A (zh) |
| MX (1) | MX2018012223A (zh) |
| PH (1) | PH12018502139A1 (zh) |
| SG (1) | SG11201808717QA (zh) |
| TW (1) | TWI798175B (zh) |
| WO (1) | WO2017176880A1 (zh) |
| ZA (1) | ZA201806530B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7023968B2 (ja) * | 2017-01-06 | 2022-02-22 | フォスプラティン・セラピューティクス・インコーポレーテッド | 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物 |
| CA3196140A1 (en) * | 2020-10-20 | 2022-04-28 | Tyler D. Ames | Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4463274B2 (ja) * | 2003-06-27 | 2010-05-19 | 明 小谷 | ビスホスホネート錯体 |
| SI2575802T1 (sl) * | 2010-06-04 | 2017-03-31 | Ohio University | Fosfaplatini in njihova uporaba za zdravljenje raznih vrst raka |
| EP2663301A1 (en) | 2011-01-12 | 2013-11-20 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| JP6027619B2 (ja) * | 2011-10-05 | 2016-11-16 | ラシンドラ・エヌ・ボーズ | ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス |
| CA2851254A1 (en) | 2011-10-05 | 2013-04-11 | Shadi MOGHADDAS | Efficient processes for large scale preparation of phophaplatins antitumor agents |
| IN2014KN02722A (zh) * | 2012-05-24 | 2015-05-08 | Phosplatin Therapeutics Llc |
-
2017
- 2017-04-05 SG SG11201808717QA patent/SG11201808717QA/en unknown
- 2017-04-05 KR KR1020187032250A patent/KR102419247B1/ko active IP Right Grant
- 2017-04-05 AU AU2017246883A patent/AU2017246883B2/en active Active
- 2017-04-05 EA EA201892157A patent/EA039525B1/ru unknown
- 2017-04-05 CA CA3020166A patent/CA3020166A1/en active Pending
- 2017-04-05 TW TW106111384A patent/TWI798175B/zh active
- 2017-04-05 CN CN201780034766.3A patent/CN109310663B/zh active Active
- 2017-04-05 US US16/091,873 patent/US11154529B2/en active Active
- 2017-04-05 WO PCT/US2017/026139 patent/WO2017176880A1/en active Application Filing
- 2017-04-05 JP JP2019503631A patent/JP2019510831A/ja active Pending
- 2017-04-05 MX MX2018012223A patent/MX2018012223A/es unknown
- 2017-04-05 BR BR112018070603A patent/BR112018070603A2/pt active Search and Examination
- 2017-04-05 EP EP17779744.6A patent/EP3439650A4/en active Pending
-
2018
- 2018-10-02 ZA ZA2018/06530A patent/ZA201806530B/en unknown
- 2018-10-02 IL IL262066A patent/IL262066A/en active IP Right Grant
- 2018-10-04 PH PH12018502139A patent/PH12018502139A1/en unknown
- 2018-10-05 CL CL2018002848A patent/CL2018002848A1/es unknown
- 2018-10-25 CO CONC2018/0011420A patent/CO2018011420A2/es unknown
-
2022
- 2022-11-04 JP JP2022177576A patent/JP2023014110A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109310663A (zh) | 2019-02-05 |
| JP2019510831A (ja) | 2019-04-18 |
| CO2018011420A2 (es) | 2019-02-08 |
| MX2018012223A (es) | 2019-05-30 |
| CL2018002848A1 (es) | 2018-12-21 |
| EA201892157A1 (ru) | 2019-04-30 |
| PH12018502139A1 (en) | 2019-09-23 |
| EP3439650A4 (en) | 2019-12-11 |
| CA3020166A1 (en) | 2017-10-12 |
| AU2017246883A1 (en) | 2018-11-08 |
| TWI798175B (zh) | 2023-04-11 |
| EP3439650A1 (en) | 2019-02-13 |
| AU2017246883B2 (en) | 2023-02-09 |
| US20200323810A1 (en) | 2020-10-15 |
| US11154529B2 (en) | 2021-10-26 |
| KR20180133889A (ko) | 2018-12-17 |
| KR102419247B1 (ko) | 2022-07-11 |
| EA039525B1 (ru) | 2022-02-07 |
| ZA201806530B (en) | 2019-07-31 |
| TW201737920A (zh) | 2017-11-01 |
| BR112018070603A2 (pt) | 2019-02-05 |
| WO2017176880A1 (en) | 2017-10-12 |
| IL262066A (en) | 2018-11-29 |
| CN109310663B (zh) | 2022-05-31 |
| JP2023014110A (ja) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809292WA (en) | Abdominal and core exerciser device | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |